Skip to main content
CellaVision logo

CellaVision — Investor Relations & Filings

Ticker · CEVI ISIN · SE0000683484 LEI · 529900IUBZBZ0HXFJ114 ST Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2023-05-05 AGM Information
Country SE Sweden
Listing ST CEVI

About CellaVision

https://www.cellavision.com/

CellaVision is a medical technology company that provides digital solutions for cell morphology in hematology. The company specializes in automating and standardizing the analysis of blood and other body fluids for both human and veterinary applications. Its core offerings include a complete system of analyzers, instruments, software, and reagents designed for hematology laboratories of all sizes. By utilizing patented technology that integrates automated microscopy, advanced image analysis, and artificial intelligence, CellaVision's systems digitize the traditional manual review of blood smears. This automation enhances laboratory workflow efficiency, improves diagnostic accuracy, and facilitates remote collaboration among healthcare professionals, advancing diagnostic certainty.

Recent filings

Filing Released Lang Actions
Bulletin from the Annual General Meeting of CellaVision AB (publ)
AGM Information Classification · 1% confidence The document explicitly states it is a "Bulletin from the Annual General Meeting of CellaVision AB (publ)" and details the resolutions passed, such as the adoption of financial statements, dividend allocation, and board member elections. This content directly relates to the proceedings and outcomes of the Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). Although it mentions dividend allocation (DIV) and board/remuneration changes (MANG/DEF 14A), the overarching context is the summary of the entire AGM event.
2023-05-05 English
Earnings Release 2023
Earnings Release Classification · 1% confidence The document provides detailed financial results for the period '1 januari– 31 mars 2023' (Q1 2023), including Net Sales, EBITDA, margins, cash flow, and management commentary on business performance across different regions (Americas, EMEA, APAC). It explicitly discusses quarterly performance metrics and outlook, which is characteristic of an Interim/Quarterly Report. The structure includes key figures, a CEO's letter summarizing the quarter, and detailed financial breakdowns. This strongly aligns with the definition of an Interim / Quarterly Report (IR). It is not a full Annual Report (10-K), an Earnings Release (ER, which is usually just the highlights), or a Call Transcript (CT). Q1 2023
2023-05-04 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the first quarter of 2023 (January 1-March 31, 2023). It contains detailed financial statements, including net sales, EBITDA, profit before tax, earnings per share, and cash flow, along with management's analysis of business performance, geographical market developments, and research and development progress. It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2023
2023-05-04 English
CellaVision announces preliminary first quarter results 2023
Earnings Release Classification · 1% confidence The document explicitly announces 'preliminary first quarter results 2023' and provides key financial highlights (Net sales, EBITDA margin) along with commentary from the CEO. This structure is characteristic of an Earnings Release (ER), which is the initial announcement of periodical financial results. Although it mentions attachments (PDFs), the core content provided is the summary of the results, making ER the most appropriate classification over RPA, especially given the detailed financial figures presented. The reference to 'EU Market Abuse Regulation' confirms it is a formal regulatory disclosure of results. Q1 2023
2023-04-17 English
CellaVision offentliggör preliminära resultat för första kvartalet 2023
Earnings Release Classification · 1% confidence The document is titled "CellaVision offentliggör preliminära resultat för första kvartalet 2023" (CellaVision publishes preliminary results for the first quarter of 2023) and provides key financial highlights (Net Sales, EBITDA margin) for Q1 2023, along with commentary from the CEO. This content structure—a brief announcement of period-specific financial results—is characteristic of an Earnings Release (ER). Although it mentions the EU Market Abuse Regulation, the core content is the preliminary financial summary, not a full comprehensive report (like an IR) or a formal regulatory filing announcement (like RPA/RNS), given its direct presentation of results. The document length (2840 chars) is short, but it contains the actual results summary, making it an ER rather than just an announcement *about* an ER. Q1 2023
2023-04-17 Swedish
Annual Report (ESEF) 2022
Annual Report (ESEF) Classification · 1% confidence FY 2022
2023-04-13 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.